No abstract available
Keywords:
BRAF inhibitor; Interstitial lung disease; MEK inhibitor; NSCLC.
MeSH terms
-
Adenocarcinoma of Lung / drug therapy*
-
Adenocarcinoma of Lung / genetics
-
Adenocarcinoma of Lung / pathology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Azetidines / administration & dosage
-
Drug Substitution / methods*
-
Humans
-
Imidazoles / administration & dosage
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Mutation*
-
Oximes / administration & dosage
-
Piperidines / administration & dosage
-
Prognosis
-
Proto-Oncogene Proteins B-raf / genetics*
-
Pyridones / administration & dosage
-
Pyrimidinones / administration & dosage
-
Vemurafenib / administration & dosage
Substances
-
Azetidines
-
Imidazoles
-
Oximes
-
Piperidines
-
Pyridones
-
Pyrimidinones
-
Vemurafenib
-
trametinib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
cobimetinib
-
dabrafenib